Anixa Biosciences (ANIX) Other financing activities (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Other financing activities came in at $3000.0 in Q4 2025, down 97.83% YoY from $138000.0 in Q4 2024, and down 97.83% on a QoQ basis from $138000.0 in Q4 2024.
Anixa Biosciences (ANIX) Other financing activities (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Other financing activities data on file, last reported at $3000.0 in Q4 2025.
- Quarterly Other financing activities fell 97.83% year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $335000.0 (down 26.54% YoY) and the FY2025 annual result came in at $7000.0, down 98.46% from the prior year.
- Other financing activities eased to $3000.0 in Q4 2025, from $138000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $22.4 million in Q2 2021 to a low of -$2.2 million in Q4 2021.
- A 5-year average of $1.5 million and a median of $71000.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities jumped 29662.13% — and 2023, when it sank 99.64%.
- Tracing ANIX's Other financing activities over 5 years: stood at -$2.2 million in 2021, then jumped by 82.29% to -$391000.0 in 2022, then jumped by 169.57% to $272000.0 in 2023, then tumbled by 49.26% to $138000.0 in 2024, then slumped by 97.83% to $3000.0 in 2025.
- The last three Other financing activities figures came in at $3000.0 (Q4 2025), $138000.0 (Q4 2024), and $194000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 3,000.00 |
| Oct 31, 2025 | 3,000.00 |
| Oct 31, 2024 | 138,000.00 |
| Oct 31, 2024 | 138,000.00 |
| Jul 31, 2024 | 194,000.00 |
| Jul 31, 2024 | 194,000.00 |
| Apr 30, 2024 | 57,000.00 |
| Apr 30, 2024 | 57,000.00 |
| Jan 31, 2024 | 67,000.00 |
| Jan 31, 2024 | 67,000.00 |
| Oct 31, 2023 | 272,000.00 |
| Oct 31, 2023 | 272,000.00 |
| Jul 31, 2023 | 3,000.00 |
| Jul 31, 2023 | 3,000.00 |
| Apr 30, 2023 | 75,000.00 |
| Apr 30, 2023 | 75,000.00 |
| Jan 31, 2023 | 3,000.00 |
| Jan 31, 2023 | 3,000.00 |
| Oct 31, 2022 | -391,000.00 |
| Oct 31, 2022 | -391,000.00 |